Akcea Therapeutics Inc. (AKCA) and Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) Comparison side by side

As Biotechnology companies, Akcea Therapeutics Inc. (NASDAQ:AKCA) and Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) are our subject to compare. And more specifically their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Akcea Therapeutics Inc. 27 11.11 N/A -1.88 0.00
Rocket Pharmaceuticals Inc. 16 0.00 N/A -1.89 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Akcea Therapeutics Inc. and Rocket Pharmaceuticals Inc.

Profitability

Table 2 provides us Akcea Therapeutics Inc. and Rocket Pharmaceuticals Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Akcea Therapeutics Inc. 0.00% -70.4% -50.3%
Rocket Pharmaceuticals Inc. 0.00% -46.8% -35.1%

Liquidity

Akcea Therapeutics Inc. has a Current Ratio of 3.3 and a Quick Ratio of 3.3. Competitively, Rocket Pharmaceuticals Inc.’s Current Ratio is 9.7 and has 9.7 Quick Ratio. Rocket Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Akcea Therapeutics Inc.

Institutional & Insider Ownership

Institutional investors owned 25.6% of Akcea Therapeutics Inc. shares and 85.9% of Rocket Pharmaceuticals Inc. shares. About 75.7% of Akcea Therapeutics Inc.’s share are owned by insiders. Comparatively, 1.8% are Rocket Pharmaceuticals Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Akcea Therapeutics Inc. -13.32% -23.67% -17.97% -14.75% -3.55% -27.9%
Rocket Pharmaceuticals Inc. -9.18% -3.64% 14.65% 0.94% -9.13% 16.19%

For the past year Akcea Therapeutics Inc. had bearish trend while Rocket Pharmaceuticals Inc. had bullish trend.

Summary

Rocket Pharmaceuticals Inc. beats on 4 of the 7 factors Akcea Therapeutics Inc.

Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease driven by high triglycerides. It has strategic collaboration with Novartis Pharma AG. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Akcea Therapeutics Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas. The company is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.